Identification of coronary heart disease in asymptomatic individuals with diabetes mellitus: to screen or not to screen by Bravo, Paco E et al.
Identification of coronary heart disease in
asymptomatic individuals with diabetes
mellitus: to screen or not to screen
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Bravo, Paco E, Bruce M Psaty, Marcelo F Di Carli, and Kelley
R Branch. 2015. “Identification of coronary heart disease in
asymptomatic individuals with diabetes mellitus: to screen or not to
screen.” Colombia Médica : CM 46 (1): 41-46.
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:16120999
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Bravo PE/et al/Colombia Médica - Vol. 46 Nº1 2015  (Jan-Mar)
41
Abstract
Coronary heart disease (CHD) is highly prevalent in patients with 
diabetes mellitus (DM), and remains the single most common cause 
of death among this population. Regrettably, a significant percentage 
of diabetics fail to perceive the classic symptoms associated with 
myocardial ischemia. Among asymptomatic diabetics, the prevalence 
of abnormal cardiac testing appears to be high, raging between 10% 
and 62%, and mortality is significantly higher in those with abnormal 
scans. Hence, the potential use of screening for CHD detection 
among asymptomatic DM individuals is appealing and has been 
recommended in certain circumstances. However, it was not until 
recently, that this question was addressed in clinical trials.  Two studies 
randomized a total of 2,023 asymptomatic diabetics to screening or 
not using cardiac imaging with a mean follow up of 4.4 ±1.4 yrs. In 
combination, both trials showed lower than expected annual event 
rates, and failed to reduce major cardiovascular events in the screened 
group compared to the standard of care alone.  The results of these 
trials do not currently support the use of screening tools for CHD 
detection in asymptomatic DM individuals. However, these studies 
have important limitations, and potential explanations for their 
negative results that are discussed in this manuscript.
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Resumen
La enfermedad de la arterias coronarias (EAC) es muy prevalente en 
pacientes con diabetes mellitus (DM), y continúa siendo la principal 
causa de muerte en estos pacientes. Desafortunadamente, muchos 
diabéticos pueden carecer de síntomas de alerta en la presencia de 
isquemia miocárdica, por lo cual el diagnóstico de EAC puede ocurrir de 
manera tardía. Estudios observacionales han sugerido que la prevalencia 
de isquemia miocárdica puede ser alta en diabéticos asintomáticos (10 
al 62% según la serie) y la mortalidad es mayor en esos pacientes. Por 
esto, el uso de pruebas para detección de EAC en el paciente diabético 
asintomático parece atractivo y es recomendado en ciertas circunstancias. 
Sin embargo, no fue si no hasta hace poco que dos estudios investigaron 
el verdadero rol de estas pruebas de manera randomizada. En conjunto, 
2,023 pacientes diabéticos asintomáticos fueron aleatorizados a recibir o 
no una prueba para detección de EAC y fueron seguidos en promedio 
por 4.4 ±1.4 años. Al final de seguimiento, ambos estudios mostraron 
menos eventos cardiovasculares de los esperados, y el uso de pruebas 
para detección de EAC no redujo la tasa de eventos cardiovasculares 
comparado al no uso de estas pruebas. Los resultados de estos ensayos 
clínicos no soportan actualmente el uso de estas pruebas en el paciente 
diabético asintomático. Sin embargo, estos estudios tienen limitaciones 
importantes, y posibles hipótesis para explicar los resultados que son 
discutidas en el artículo.
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Introduction
Diabetes mellitus (DM) is a major public health problem in 
the United States (U.S.) and worldwide. The age-adjusted U.S. 
prevalence (per 100 persons) of diagnosed DM cases has increased 
in the last two decades from 3.5 (95%CI, 3.2-3.9) in 1990 to 8.3 
(95%CI, 7.9-8.7) in 20121. More concerning, the percentage of 
individuals with DM in 2012 was 16.2% for the age group 45-64 
and 25.9% for people age 65 or older2.
Diabetes is a major risk factor for the development of coronary 
heart disease (CHD) and its most severe complications myocardial 
infarction (MI), sudden cardiac death (SCD) and congestive heart 
failure (CHF)3,4. Consequently, cardiovascular morbidity and 
mortality are disproportionately high among individuals with DM 
compared to those without. For instance, the age-adjusted rates 
of hospitalization for MI and cardiovascular deaths are 1.8 and 
1.7 times higher respectively among adult diabetics than non-
diabetic individuals2. Moreover, a study published by Haffner 
et al., revealed that individuals with long-standing type 2 DM 
(mean duration 8.06 ±0.14 yrs), but without prior MI history, have 
similar rates of MI and cardiac deaths compared to non-diabetics 
with a previous MI3. Appropriately, the U.S. guidelines for the 
management of lipids treat DM as a CHD risk-equivalent5, and 
many care providers may have a low threshold for performing 
non-invasive as well as invasive testing to identify CHD among 
individuals with DM.
Prevalence of sub-clinical coronary heart disease among diabetics
Individuals with DM appear to be less able to perceive some of 
the classic symptoms associated with ischemia, and may have 
asymptomatic “silent myocardial ischemia”. This can eventually 
manifest as silent or clinical MI, CHF, or even SCD. Scott et al., 
described the clinical characteristics of 61 patients with healed 
transmural MI on necropsy of which only 33 had a clinical 
history of acute MI6. In patients with MI on autopsy, DM was 
significantly more common in those without a clinical history 
of MI (46%) as compared to those with a prior history of MI 
(15%)6. Similarly, the prevalence of abnormal stress imaging 
scans as a measure of myocardial ischemia or scar is high among 
asymptomatic DM individuals7-15. Depending on the populations 
studied and inclusion criteria, the percentage of DM patients with 
abnormal scans range widely between 10% and 62%  (Table 1)13-
17. De Lorenzo, et al.,  examined 180 asymptomatic DM subjects 
(disease duration not specified) with rest and stress single photon 
emission computed tomography (SPECT)14 for pre-operative 
evaluation or for screening of asymptomatic CHD. The prevalence 
of abnormal SPECT scans (defined as ischemia, scar or both) was 
26%. Rajagopalan et al., performed rest and stress SPECT on 1,427 
relatively high-risk, asymptomatic (mostly type 2) DM individuals 
(median duration 10 yrs)14. The indications for SPECT evaluation 
included pre-operative assessment, screening, and non-specific 
symptoms (other than angina or dyspnea). Importantly, 9% of the 
subjects had evidence of Q-waves on electrocardiogram suggestive 
of prior MI. The frequency of abnormal SPECT studies was high 
(58%) in the study population, and 18% of patients had high-risk 
scans. Finally, Scognamiglio et al., studied 1,899 asymptomatic 
type 2 DM patients (duration 9.3 ±5.6 yrs) with dipyridamole 
myocardial contrast echocardiography (MCE) followed by 
invasive coronary angiography for those with positive MCE17. 
Of the 60% of individuals with abnormal MCE, 65% (736/1,133) 
had ≥50% luminal diameter narrowing of one or more major 
epicardial coronary arteries or major branches. Importantly, the 
prevalence of three-vessel CHD was 7.6% among patients with 
abnormal MCE and ≤1 associated risk factors, but 33.3% in those 
with abnormal MCE and ≥2 risk factors17.
Author Study* Indication N Age DM Dura-tion (yrs)** Modality Abnormal study# Follow-up (yrs)**
Cardiac Deaths n:(%) Non-fatal MI  n:(%) Annual Cardiovascular Event Rate§ (%) Risk Ratio for Abnormal Study (95% CI)Normal study Abnormal study All patients Normal studies Abnormal studies All   patients Normal study Abnormal study All    patients
Torremocha, 20017 1 72 55±7 15 (1-49) SPECT and treadmill 8 (11) 3.25 ± 1.0 1(1.6) 1(12.5) 2 (2.8) 2 (3) 0 (0) 2 (2.8) 2.9 7.7 3.4 2.7 (0.64-11.0)Le Feuvre, 20058 1 100 61±10 14±9.0 SPECT and DSE 62 (62) 2.0 ± 0.5 0 0 0 0 2 (3.2) 2 (2) 5.3 4.4 4.5 0.8    (0.2-2.7)!Sejil, 20069 1 203 54±13 18±7.6 SPECT and/or treadmill 32 (16) 6 4 (2.5) 2 (6.5) 6 (3.0) n/a n/a n/a 1.6 5.9 2.3 3.7    (1.9-7.3)!
Sholte, 200910 1 120 53±10 9.5±7.3 SPECT 40 (33) 1 0 0 0 0 0 0 1.3 12.5 5.0 10.0 (1.2-82.7)!
Choi, 200911 1 116 62±7 11.1± 6.9 SPECT and CCTA 28 (24) 2.0 ± 0.3 1 (1.1) 1 (3.6) 2 (1.7) 0 0 0 2.8 5.4 3.4 1.9    (0.5-7.4)!Jacqueminet, 201012 1 204 65±6 15±9.0 SPECT or DSE 25 (12) 3.0 ± 1.1 n/a n/a 3 (1.5) n/a n/a 2 (1.0) n/a n/a 8.0 n/a
Giovacchini, 201313 1 77 63±9 8.9±6.3 SPECT 25 (32) 4.1 (0.8-6.1) n/a n/a 5 (6.5) n/a n/a 2 (2.6) n/a n/a 2.2 2.8    (0.6-12.5)
De Lorenzo, 200214 1, 2 180 61±10 n/a SPECT 46 (26) 3.0 ± 1.5 n/a n/a 7 (3.9) n/a n/a 6 (3.3) 1.2 5.8 2.4 4.7 (1.6 - 13.5)!
Yamasaki, 201015 3 485 67±8 n/a SPECT 47 (9.7) 3 n/a n/a 5 (1.0) n/a n/a 9 (1.9) n/a n/a 1.0 1.9 times* Study indication: 1 = screening, 2 = pre-operative, 3 = unclear/not stated** Duration and follow-up given as mean ± standard deviation or median (interquartile range)
# Definition of abnormal study varies from study to study. Values: n(%)  
§ Definition of cardiovascular hard events varies significantly from study to study, and includes cardiac mortality, non-fatal MI, unstable angina, heart failure admission, coronary revascularization, stroke! Calculated by our group as not provided by the authors SPECT = single photon emission computed tomography, CCTA = coronary computed tomography angiography, MCE = Dipyridamole stress myocardial contrast echo, DSE = Dobutamine stress echocardiography, MI = myocardial infarction, n/a = not available
Table 1. Summary of observational studies using cardiac testing for evaluation of coronary heart disease and cardiovascular outcomes in apparently 
asymptomatic individuals with diabetes mellitus
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The aforementioned literature highlights the relative high 
frequency of abnormal cardiac stress testing findings and CHD 
on coronary angiography among those with abnormal studies in 
seemingly asymptomatic individuals with DM. However, routine 
screening in asymptomatic individuals is not part of current 
guidelines and the role of testing is unclear.
Role of screening asymptomatic diabetic individuals for coronary 
heart disease
The discordance between the apparently high prevalence of CHD 
and lack of warning symptoms, such as chest pain, has been 
attributed to diabetic autonomic neuropathy involving the cardiac 
afferent sympathetic fibers, which are a key component of cardiac 
pain perception. The early clinical manifestations of CHD may not 
be perceived or they may be atypical or non-specific. As a result, 
more severe presentations of ischemia --acute MI, SCD or advanced 
CHF-- may be the first clinical presentation of CHD in DM.
 
A number of observational studies have tried to investigate the 
potential role of CHD screening in seemingly asymptomatic 
DM individuals by evaluating the cardiovascular outcomes after 
cardiac testing that included rest/stress SPECT, treadmill ECG, 
stress echocardiography, and coronary computed tomography 
angiography (CCTA; Table 1)7-15. Using hard (e.g. cardiac 
mortality, and non-fatal MI), as well as more subjective (e.g. 
coronary revascularization) major adverse cardiovascular events 
as endpoints, most studies indicated that patients with abnormal 
or high risk cardiac testing had significantly higher annual rates of 
events compared to individuals with normal or low-risk cardiac 
testing (Table 1).  For example, De Lorenzo et al., reported that 
non-fatal MI or cardiac death rates were 2% per year for normal 
SPECT versus 9% per year for those with abnormal SPECT scans 
over 3.0 ±1.5 yrs of follow up. Rajagoapalan, et al., reported the 
annual mortality rate of 5.9% for high risk, 5.0% for intermediate-
risk, and 3.6% for low risk SPECT scans after 5.8 ±3.5 yrs of follow-
up. These data suggest that asymptomatic ischemia and infarction 
are not uncommon and when present, portends a graded risk of 
cardiovascular events depending on the degree of ischemia.
The results of these, and other observational, non-randomized 
studies, suggest that the use of screening tools for identification 
of CHD in asymptomatic DM individuals may be appealing and 
has been recommended in certain circumstances18. However, the 
main limitation of these observational cohorts studies is that they 
are not really “testing” the role of screening and the benefit of any 
interventions that may follow. The optimal method of evaluating a 
screening test is a randomized trial.
Recently, two clinical trials have now addressed this question 
by randomizing asymptomatic DM patients to screening or not 
using cardiac SPECT19, 20 or CCTA21. The Detection of Ischemia 
in Asymptomatic Diabetics (DIAD) study was a multicenter 
prospective trial in the U.S. and Canada of asymptomatic patients 
with type 2 DM without known or suspected CHD19. Between 
July 2000 and August 2002, 1,123 subjects were randomized to 
either screening rest/stress SPECT (n= 561) or continued on the 
standard of care (n= 562) and followed for approximately 5 yrs. 
The mean DM duration at randomization was 8.2 ±7.1 yrs in the 
screened group and 8.9 ± 6.9 yrs in the control group (Table 2). 
Preliminary findings revealed that 22% (113/522) of the screening 
SPECT images were consistent with silent ischemia although only 
6% (n= 33) had moderate or large stress perfusion defects19. The 
primary outcome of cardiac death or non-fatal MI over the mean 
4.8 yrs follow up was relatively low with a cumulative cardiac event 
rate of 2.9% or 0.6% per year20. Most importantly, the number of 
cardiac events did not differ between the screening SPECT and 
standard of care groups. Only 7 non-fatal MI and 8 cardiac deaths 
(2.7%) occurred in the screened group and 10 non-fatal MI and 7 
cardiac deaths (3.0%) among the standard of care group (HR, 0.88; 
95%CI, 0.44-1.88; p= 0.73). Coronary angiography (4.4% vs. 0.5%; 
p <0.001) and revascularization (1.6% vs. 0.36%; p= 0.03) were 
performed more frequently in the screened than control group 
during the first 120 days after randomization, likely as a result 
of abnormal SPECT scans. However, the overall rate of coronary 
angiography (14% vs. 12%; p= NS) and coronary revascularization 
(5.5% vs. 7.8%; p= 0.14) were comparable in the screened and 
unscreened group after the conclusion of the 5-year follow-up 
period.  Importantly, during the course of the trial there was a 
significant and equivalent increase in primary prevention medical 
treatments, including aspirin, statins and angiotensin converting 
enzyme inhibitors, in both groups. Thus, data from the DIAD 
study suggest that screening asymptomatic type 2 DM patients 
with SPECT stress testing did not reduce the cardiac events 
compared to contemporary standard of care.
Table 2. Cardiovascular outcomes after randomization of asymptomatic individuals with diabetes mellitus to screening for evaluation of 
coronary heart diseaseTrial DIAD, 200920 FACTOR-64, 201421 TotalModality SPECT CCTAGroup Screened No Screening Screened No Screening Screened No ScreeningSize, N 561 562 452 448 1,013 1,010Age, year ± SD 60.7 ± 6.7 60.8 ± 6.4 61.5 ± 7.9 61.6 ± 8.3 61.1 ± 7.3 61.2 ± 7.3Males, N (%) 290 (52) 311 (55) 234 (52) 235 (53) 524 (52) 546 (54)DM Duration, year ± SD 8.2 ± 7.1 8.9 ± 6.9 12 ± 9 13.5 ± 11 9.9 ± 8.2 10.9 ± 9.2Cardiac Deaths, N (%) 8 (1.4) 7 (1.2) 7 (1.5) 8 (1.8) 15 (1.5) 15 (1.5)Non-fatal MI, N (%) 7 (1.2) 10 (1.8) 7 (1.5) 8 (1.8) 14 (1.4) 18 (1.8)Annual Event Rate (%) 0.6 0.6 0.8 0.9 0.7 0.7Hazard Ratio for Screening              0.89 (0.4-1.9)                      0.87 (0.4-1.8)                      0.87 (0.5-1.4)Follow-up year ± SD             4.8 ± 0.9                    4.0 ± 1.7                      4.4 ± 1.4DIAD= Detection of Ischemia in Asymptomatic Diabetics, SPECT= single photon emission computed tomography, CCTA= coronary computed tomography angiography; DM= diabetes mellitus, MI= myocardial infarction.
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A more recent trial, the FACTOR-64 study randomized 900 high-
risk, asymptomatic patients with type 1 or type 2 DM to screening 
CCTA scan followed by a specific treatment plan based on CCTA 
findings (n= 452) or to the standard of care (n= 447)21. Mean DM 
duration was 12.3 ±9.23 and 13.5 ±10.7 yrs in the screened and 
control group, respectively. The primary composite outcome was 
all-cause mortality, non-fatal MI, or unstable angina. According 
to CCTA results, prevalence of severe (defined as ≥70% stenosis 
in at least 1 major proximal or large coronary artery) or moderate 
CHD (50% - 69% stenosis or coronary artery calcium score >100) 
was 6.3% (n=21), and 10.7% (n=36) respectively in the screened 
population. Similar to the DIAD Study, the overall proportion of 
patients undergoing coronary angiography (13.3% vs. 5.1%) or 
revascularization with percutaneous coronary intervention (6.0% 
vs. 1.8%) or coronary artery bypass graft surgery (2.9% vs. 1.3%) 
were more common in the CCTA screened population than the 
standard of care group. Nevertheless, at a mean follow-up time of 
4.0 ±1.7 yrs, the primary composite end-point was similar in both 
groups (6.2 and 7.6%, respectively). A total of 16 all-cause deaths, 
7 non-fatal MI and 9 hospitalizations for unstable angina (6.2%) 
were seen in the screened group, 19 all-cause deaths, 8 non-fatal MI 
and 9 hospitalizations for unstable angina (7.6%) occurred in the 
control group (HR, 0.80; 95%CI, 0.49-1.32; p= 0.38). The incidence 
of the composite secondary end point of ischemic major adverse 
cardiovascular events also did not differ between groups (4.4%: 20 
events vs. 3.8%: 17 events; HR: 1.15; 95%CI: 0.60-2.19; p= 0.68).  
In summary, the FACTOR-64 trial showed that screening 
asymptomatic patients with DM using CCTA, a modality 
that primarily serves as an anatomical rather than functional 
estimation of ischemia, failed to reduce major cardiovascular 
events compared to the standard of care alone.  
Potential explanations for the lack of benefit of screening in these 
two trials are numerous. First, the sample size of both studies 
combined was 2,023 participants and in the presence of lower 
than expected annual event rates (<1.0% per year in both trials), 
it is conceivable that these studies may have been underpowered. 
For example, looking at the control (no screening) groups of 
DIAD (n= 562) and FACTOR-64 (n= 448), the combined number 
of cardiac deaths (n= 15) and non-fatal MI (n= 18) was only 33, 
representing a cumulative event rate of 3.3% after a mean follow-
up of 4.4 yrs.  Calculation of sample size will partly depend on the 
effectiveness of the intervention (e.g. coronary revascularization) 
to reduce event rates in the screening compared to the control 
group. Assuming 80% power, and an alpha of 0.05 for a 2-tailed 
test, the estimated sample size for each group would be 3,547, 3,108 
and 831 individuals for an intervention with 20% (3.3% to 2.6%), 
30% (3.3% to 2.3%) and 40% (3.3% to 1.98%) event reduction 
rates respectively.  This means that the combination of both trials, 
theoretically, would have yielded adequate power (n= 2,023) to detect 
significant differences if the intervention(s) were capable of causing 
a 40% event reduction in the screened group. This clinical effect was 
obviously not seen in either trial. From this hypothetical exercise, one 
could argue that a significantly larger study (>6,000 subjects) would 
be required to detect a clinically important relative risk reduction of 
20% to 30% in cardiac mortality or non-fatal MI among screened 
individuals. Furthermore, perhaps a longer follow-up than the mean 
4.4 yrs duration for both studies could also aid detect more clinical 
differences between the screening and no screening groups.
Additional potential contributors to the low event rate observed 
may also be the types of patients enrolled in the trials. Population-
based studies have reported that the duration of DM (usually 
of more than 10 years’ duration) appears to be an important 
determinant in the prediction of adverse cardiovascular events, 
especially among DM men aged 60 and 7922. In this respect, 
FACTOR-64 enrolled men ≥50  yrs or women ≥55 yrs with DM 
documented for at least 3 years or men ≥40  years or women ≥45 
yrs with DM for at least 5 yrs, whereas, DIAD recruited patients 
between the ages of 50 and 75 yrs with type 2 DM onset at age 
≥30 yrs. Mean DM duration was 12.7 ±10 yrs, and 8.5 ±7.0 yrs 
in FACTOR-64 and DIAD, respectively. Therefore, patients in the 
DIAD study and perhaps less so in the FACTOR-64 did not have an 
adequately long duration of DM to be considered “high risk” and 
therefore potentially benefit from revascularization. Future studies 
may be required to further investigate if CHD screening is suitable in 
a specific subset of higher-risk DM individuals without symptoms.
Another point worth discussing is the low prevalence of significant 
CHD in these trials. For example, in DIAD, even though 22% of 
the screened individuals had abnormal SPECT, only 6% of them 
were considered to have high-risk scans. Similarly, in FACTOR-64 
only 6.3% of screened patients had CCTA evidence of severe CHD. 
This is an important fact as most observational studies in the 
literature (Table 1) suggest higher prevalence of abnormal cardiac 
scans and/or CHD, which is likely explained by differences in the 
grading systems of abnormal cardiac testing and/or definitions of 
CHD, as well as a wide variation in inclusion/exclusion criteria 
between studies. In this last aspect, clinical trials are undoubtedly 
more selectively performed (e.g. DIAD excluded patients with 
abnormal electrocardiograms), potentially minimizing the 
chances of enrolling people with more overt CHD.
Lastly, in the DIAD and FACTOR-64 trials, significant 
improvements in medical management were also seen over 
time.  In the DIAD study, nearly 2/3 of patients, irrespective of 
randomization group, were taking aspirin (~73%), statins (~67%) 
or anti-hypertensive drugs (~74%) by the end of the 5-year 
follow-up period. In a similar way, in FACTOR-64, LDL (74% of 
patients were on statins), and systolic blood pressure were usually 
at goal, implying adequate medical regimens in both groups, 
which may have contributed significantly to the low cardiac event 
rates observed in both trials.  These findings may be supported 
by the results from the COURAGE (34% had DM) and BARI 2D 
(all patients had type 2 DM) trials where major cardiovascular 
events were similar between optimal medical therapy alone or 
with coronary revascularization in symptomatic patients with, 
otherwise, stable CHD23,24. Although this is only hypothesis 
generating, the cumulative data does not suggest that coronary 
revascularization should be performed for all DM patients with 
CHD and ischemia. 
Both the DIAD and FACTOR-64 studies clearly highlight 
the importance of sponsoring and conducting well-designed 
randomized clinical trials to confirm or dispute (such as in this 
case) previously made assumptions from observational data 
that is subject to a number of inherent bias and limitations. The 
prospective, randomized ISCHEMIA trial of revascularization 
versus optimal medical therapy alone in symptomatic patients with 
moderate to severe ischemia may shed further light on the role of 
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revascularization in truly higher risk patients. However, additional 
trials in the highest risk, asymptomatic DM patients are needed for 
definitive assessment of benefit or lack of benefit of screening.
Conclusion
Screening using non-invasive cardiac imaging with either SPECT 
or CCTA for occult or undiagnosed CHD in asymptomatic 
DM individuals is not supported by two moderately sized, well-
conducted, randomized trials.  Given the lower than expected 
rates of major cardiovascular events in the trials, optimal medical 
therapy appears important.  Additional data on the benefits in 
higher risk, asymptomatic DM patients with longer DM duration 
or with higher risk scans are needed.   
Conflicts of interest:
Dr. Psaty serves on the DSMB for a clinical trial of a device funded 
by the manufacturer (Zoll LifeCor) and on the steering committee 
of the Yale Open Data Access Project funded by Johnson & 
Johnson.
Acknowledgment:
We would like to thank Charles C. Maynard, PhD, Research 
Professor Emeritus, Department of Health Services, School of 
Public Health, University of Washington, Seattle, for his helpful 
assistance with statistical analysis.
References
1. Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, Li Y, et 
al. Prevalence and incidence trends for diagnosed diabetes among 
adults aged 20 to 79 years, united states, 1980-2012. JAMA. 2014; 
312: 1218–26. 
2. CDC . National diabetes statistics report. Atlanta, GA, U.S: 
Department of Health and Human Services; 2014.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. 
Mortality from coronary heart disease in subjects with type 2 
diabetes and in nondiabetic subjects with and without prior 
myocardial infarction. New England J Med. 1998; 339: 229–34. 
4. Zaccardi F, Khan H, Laukkanen JA. Diabetes mellitus and risk 
of sudden cardiac death: A systematic review and meta-analysis. 
Internat J Cardiol. 2014; 177: 535-37
5. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer 
FE, et al. The impact of diabetes mellitus on mortality from all 
causes and coronary heart disease in women: 20 years of follow-
up. Arch Int Med. 2001; 161: 1717–23. 
6. Cabin HS, Roberts WC. Quantitative comparison of extent 
of coronary narrowing and size of healed myocardial infarct in 
33 necropsy patients with clinically recognized and in 28 with 
clinically unrecognized ("silent") previous acute myocardial 
infarction. Am J Cardiol. 1982;50:677–681. 
7. Torremocha F, Hadjadj S, Carrie F, Rosenberg T, Herpin D, 
Marechaud R. Prediction of major coronary events by coronary 
risk profile and silent myocardial ischaemia: Prospective follow-
up study of primary prevention in 72 diabetic patients. Diabetes 
Metab. 2001; 27: 49–57. 
8. Le Feuvre CL, Barthelemy O, Dubois-Laforgue D, Maunoury 
C, Mogenet A, Baubion N, et al. Stress myocardial scintigraphy 
and dobutamine echocardiography in the detection of coronary 
disease in asymptomatic patients with type 2 diabetes. Diabetes 
Metab. 2005; 31: 135–42. 
9. Sejil S, Janand-Delenne B, Avierinos JF, Habib G, Labastie N, 
Raccah D, et al. Six-year follow-up of a cohort of 203 patients with 
diabetes after screening for silent myocardial ischaemia. Diabetic 
medicine : J British Diabetic Assoc. 2006; 23: 1186–91.
10. Scholte AJ, Schuijf JD, Kharagjitsingh AV, Dibbets-Schneider 
P, Stokkel MP, et al. van der Wall EE Prevalence and predictors of 
an abnormal stress myocardial perfusion study in asymptomatic 
patients with type 2 diabetes mellitus. Eur J Nuclear Med Mol 
Imag. 2009; 36: 567–75.
11. Choi EK, Chun EJ, Choi SI, Chang SA, Choi SH, Lim S, 
et al. Assessment of subclinical coronary atherosclerosis in 
asymptomatic patients with type 2 diabetes mellitus with single 
photon emission computed tomography and coronary computed 
tomography angiography. Am J Cardiol. 2009; 104: 890–6. 
12. Jacqueminet S, Barthelemy O, Rouzet F, Isnard R, Halbron M, 
Bouzamondo A, et al. A randomized study comparing isotope 
and echocardiography stress testing in the screening of silent 
myocardial ischaemia in type 2 diabetic patients. Diabetes Metab. 
2010;36: 463–9. 
13. Giovacchini G, Cappagli M, Carro S, Borrini S, Montepagani 
A, Leoncini R, et al. Microalbuminuria predicts silent myocardial 
ischaemia in type 2 diabetes patients. Eur J Nuclear Med Mol 
Imag. 2013;40: 548–57.
14. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. 
Prevalence and prognostic value of perfusion defects detected by 
stress technetium-99m sestamibi myocardial perfusion single-
photon emission computed tomography in asymptomatic patients 
with diabetes mellitus and no known coronary artery disease. Am 
J Cardiol. 2002; 90: 827–32. 
15. Yamasaki Y, Nakajima K, Kusuoka H, Izumi T, Kashiwagi A, 
Kawamori R, et al. Prognostic value of gated myocardial perfusion 
imaging for asymptomatic patients with type 2 diabetes: The 
j-access 2 investigation. Diabetes Care. 2010; 33: 2320–6. 
16. Rajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ. 
Identifying high-risk asymptomatic diabetic patients who are 
candidates for screening stress single-photon emission computed 
tomography imaging. J Am Coll Cardiol. 2005; 45: 43–9. 
17. Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro 
A. Detection of coronary artery disease in asymptomatic patients 
with type 2 diabetes mellitus. J Am Coll Cardiol. 2006; 47: 65–71.
 
18. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff 
MJ, Fayad ZA, et al. 2010 accf/aha guideline for assessment of 
cardiovascular risk in asymptomatic adults: Executive summary: A 
report of the american college of cardiology foundation/american 
heart association task force on practice guidelines. Circulation. 
2010; 122: 2748–64. 
Bravo PE/et al/Colombia Médica - Vol. 46 Nº1 2015  (Jan-Mar)
46
Colomb Med. 46(1):41-6
19. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey 
JA, Barrett EJ, et al. Detection of silent myocardial ischemia in 
asymptomatic diabetic subjects: The diad study. Diabetes Care. 
2004; 27: 1954–61. 
20. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett 
EJ, Taillefer R, et al. Cardiac outcomes after screening for 
asymptomatic coronary artery disease in patients with type 2 
diabetes: The DIAD study: A randomized controlled trial. JAMA. 
2009; 301: 1547–55. 
21. Muhlestein JB, Lappe DL, Lima JA, Rosen BD, May HT, Knight 
S, et al. Effect of screening for coronary artery disease using ct 
angiography on mortality and cardiac events in high-risk patients 
with diabetes: The factor-64 randomized clinical trial. JAMA. 
2014; 312: 2234-43.
22. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar 
N. Impact of diabetes on cardiovascular disease risk and all-
cause mortality in older men: Influence of age at onset, diabetes 
duration, and established and novel risk factors. Arch Int Med. 
2011; 171: 404–10. 
23. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, 
Kostuk WJ, et al. Optimal medical therapy with or without pci for 
stable coronary disease. New England J Med. 2007; 356: 1503–16. 
24. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, 
MacGregor JM, et al. A randomized trial of therapies for type 2 
diabetes and coronary artery disease. New England J Med. 2009; 
360: 2503–15. 
